Colchicine: A Dual Therapeutic Target for Trichinellosis
Acta Parasitologica,
Год журнала:
2025,
Номер
70(1)
Опубликована: Янв. 24, 2025
Abstract
Purpose
Trichinellosis
affects
around
11
million
people
globally.
Treatments
for
this
medical
condition
are
limited
by
adverse
effects
and
resistance,
emphasising
the
importance
of
effective
safe
therapies.
Consequentially,
we
sought
to
study
colchicine’s
synergistic
with
atorvastatin
or
acetazolamide
in
treatment
Trichinella
spiralis
(
T.
spiralis)
-infected
mice.
Methods
Seventy
mice
were
evenly
divided
into
two
groups
(a
b)
35
each.
During
intestinal
phase,
group
(a)
began
therapy
on
second
day
post-infection
(dpi)
lasted
four
days.
Group
(b)
had
weeks
during
muscle
beginning
12th
dpi.
While
other
five
infected
received
atorvastatin,
colchicine,
acetazolamide,
a
combination
none,
one
no
at
all
as
negative
control.
The
efficacy
was
assessed
parasite
count,
histopathology
scanning
electron
microscopy.
Results
Our
data
revealed
that
lowered
adult
worm
larvae
counts
animals.
Moreover,
it
restored
normal
muscular
architecture,
reduced
edema,
alleviated
inflammation,
demonstrated
inflammatory
infiltrate.
Scanning
microscopic
examination
adults
verified
our
findings.
Conclusion
Adjuvant
colchicine
an
antifibrotic
can
help
treat
trichinellosis
reducing
production
fibrous
tissue.
This
might
enhance
results
enabling
admission
larvicidal
medications
and,
result,
number
muscle,
which
together
form
basis
pathology
be
debilitating
patient.
Язык: Английский
The Role of Cardiac Magnetic Resonance in mRNA COVID-19 Vaccine-Related Myopericarditis: An Evolutive Case Series
Journal of Cardiovascular Development and Disease,
Год журнала:
2024,
Номер
11(9), С. 259 - 259
Опубликована: Авг. 25, 2024
Numerous
cases
of
myocarditis
related
to
mRNA
vaccines
for
COVID-19
have
recently
been
described,
usually
in
young
men.
Long-term
evolutive
cardiac
magnetic
resonance
imaging
(CMR)
data
are
lacking.
We
describe
four
consecutive
vaccine-induced
myocarditis.
The
pathological
findings
confirmed
the
diagnosis
acute
phase,
showing
edema,
as
well
pericardial
enhancement,
with
light
effusion
and
late
gadolinium
enhancement
(LGE),
predominantly
inferolateral
wall.
These
highlight
unique
value
patients
suspected
induced
by
RNAm
a
tool
confirm
diagnosis,
avoiding
other
invasive
techniques,
long-term
follow-up
patients.
Our
iterative
CMR
demonstrated
frequent
LGE
persistence.
Язык: Английский
Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action
Heliyon,
Год журнала:
2024,
Номер
10(16), С. e35988 - e35988
Опубликована: Авг. 1, 2024
Язык: Английский
A Comprehensive Review of Colchicine: An Ancient Drug with Many Therapeutic Potentials
International Journal of Pharmaceutical and Phytopharmacological Research,
Год журнала:
2024,
Номер
14(4), С. 17 - 22
Опубликована: Янв. 1, 2024
Язык: Английский
Colchicine: Repositioning an “ancient” medicine in the 21st century
Rheumatology Science and Practice,
Год журнала:
2024,
Номер
62(5), С. 445 - 464
Опубликована: Окт. 31, 2024
The
main
indications
for
colchicine
treatment
until
recently
were
gout,
pericarditis,
familial
Mediterranean
fever
and
some
other
auto-inflammatory
diseases.
expansion
of
(repositioning)
the
use
in
direction
prevention
cardiovascular
complications
should
be
considered
as
one
major
events
medicine
XXI
century.
Deciphering
role
inflammation
most
important
mechanism
development
atherosclerosis
has
created
prerequisites
concept
anti-inflammatory
therapy
atherosclerosis,
which
low-dose
can
take
an
place,
complementing
effects
aspirin,
statins
antihypertensive
therapy.
analysis
materials
from
randomized
placebo-controlled
studies
indicates
a
decrease
frequency
patients
with
coronary
heart
disease
(by
31%)
who
have
suffered
myocardial
infarction
23%),
well
33%),
stroke,
need
revascularization
mortality.
low
dose
(0.5
mg/day)
is
approved
by
U.S.
Food
Drug
Administration
disease.
It
assumed
that
future
will
place
pathology
associated
atherosclerotic
vascular
Язык: Английский